What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
His primary scientific interests are in Ovarian cancer, Internal medicine, Surgery, Oncology and Cancer.
His research integrates issues of Cancer research, Carcinoma, Ascites and Gynecology in his study of Ovarian cancer.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Endocrinology.
His research investigates the connection with Surgery and areas like Hazard ratio which intersect with concerns in Retrospective cohort study.
Jalid Sehouli works mostly in the field of Oncology, limiting it down to concerns involving Clinical trial and, occasionally, Randomized controlled trial.
His Cancer study integrates concerns from other disciplines, such as Prospective cohort study, Disease and Palliative care.
His most cited work include:
- A phase 3 trial of bevacizumab in ovarian cancer. (1288 citations)
- Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse (386 citations)
- Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. (320 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Ovarian cancer, Oncology, Surgery and Chemotherapy.
His Carboplatin, Ascites and Recurrent Ovarian Cancer study in the realm of Internal medicine interacts with subjects such as In patient.
His work in Carboplatin is not limited to one particular discipline; it also encompasses Paclitaxel.
He usually deals with Ovarian cancer and limits it to topics linked to Cancer research and Ovarian carcinoma.
His Oncology research is multidisciplinary, incorporating perspectives in Clinical trial, Phases of clinical research, Topotecan, Advanced ovarian cancer and Bevacizumab.
Surgery is often connected to Cervical cancer in his work.
He most often published in these fields:
- Internal medicine (51.62%)
- Ovarian cancer (44.23%)
- Oncology (38.45%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (51.62%)
- Ovarian cancer (44.23%)
- Oncology (38.45%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Ovarian cancer, Oncology, Cancer research and Chemotherapy.
His study on Quality of life, Cancer and Bevacizumab is often connected to In patient as part of broader study in Internal medicine.
The various areas that Jalid Sehouli examines in his Ovarian cancer study include Serous fluid, Ascites, Clinical endpoint, Disease and Stage.
His research in Serous fluid intersects with topics in Ovarian carcinoma, Biomarker and Tissue microarray.
His work carried out in the field of Oncology brings together such families of science as Debulking, Serous ovarian cancer, Vulvar cancer, Recurrent Ovarian Cancer and Cohort.
Between 2017 and 2021, his most popular works were:
- ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (180 citations)
- A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms (138 citations)
- The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. (58 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Surgery
Jalid Sehouli mainly investigates Internal medicine, Ovarian cancer, Oncology, Cancer research and Serous fluid.
His research in the fields of Chemotherapy and Carboplatin overlaps with other disciplines such as In patient.
His Ovarian cancer study deals with the bigger picture of Cancer.
His work in Oncology covers topics such as Recurrent Ovarian Cancer which are related to areas like Clinical trial and Surgery.
In his research, Immunohistochemistry and Meta-analysis is intimately related to Biomarker, which falls under the overarching field of Cancer research.
His studies deal with areas such as Ovarian carcinoma, Machine learning, Tissue microarray and Artificial intelligence as well as Serous fluid.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
